Contact details

 

Prof Stefan Knapp

Email: knapp (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29871

Stefan studied Chemistry at the University of Marburg (Germany) and at the University of Illinois (USA). He did his PhD in protein crystallography at the Karolinska Institute in Stockholm (Sweden) (1996) and continued his career at the Karolinska Institute as a postdoctoral scientist (1996-1999). In 1999, he joined the Pharmacia Corporation as a principal research scientist in structural biology and biophysics. He left the company in 2004 to set up a research group at the Structural Genomics Consortium at Oxford University (SGC). From 2008 to 2015 he was a Professor of Structural Biology at the Nuffield Department of Clinical Medicine (NDM) at Oxford University (UK) and between 2012 and 2015 he was the Director for Chemical Biology at the Target Discovery Institute (TDI). He joined Frankfurt University (Germany) in 2015 as a Professor of Pharmaceutical Chemistry and the Buchmann Institute of Molecular Life Sciences. He remains associated to the SGC as a visiting Professor at Oxford and he is also adjunct Professor of the George Washington University. Since 2017 he is the CSO of the newly founded SGC node at the Goethe-University Frankfurt. His research interests are the rational design of selective inhibitors that target protein kinases as well as protein interactions modules that function as reader domains of the epigenetic code.

 

 

Ivan Dikic, Prof MD PhD
Email: dikic (at) biochem2.de
Tel: +49 (0)69 6301-5652

Ivan was trained as a medical doctor in his hometown Zagreb (Croatia), before joining the lab of Joseph Schlessinger in New York in 1992 to pursue a PhD thesis in molecular biology. He moved back to Europe in 1997 to start his own group at the Ludwig Institute for Cancer Research in Uppsala (Sweden). In 2002, Ivan accepted a professorship at Goethe University and was appointed as director of the Institute of Biochemistry II in 2009. In parallel, he was the founding director of the Buchmann Institute for Molecular Life Sciences (BMLS), where he still sustains an outstation lab. His research is dedicated to deciphering the molecular mechanisms of cellular signaling pathways, which have a high relevance to human diseases such as cancer, neurodegenerative disorders and inflammation. Ivan is the speaker of Germany's first collaborative research network on autophagy (SFB 1177, www.sfb1177.de) and part of the local steering boards for the German Cancer Consortium (DKTK) and the SGC. Ivan was awarded with numerous recognitions, amongst them the Gottfried Wilhelm Leibniz Prize 2013 and election to the German National Academy of Sciences Leopoldina.

 

 

Masato Akutsu
Email: akutsu (at) em.uni-frankfurt.de
Tel: +49 (0)69 798-42535

Masato obtained his PhD in 2007 from The Graduate University for Advanced Studies, Japan. For his post-doctoral studies, Masato moved to The Structural Genomics Consortium, University of Toronto, Canada and MRC - Laboratory of Molecular Biology, Cambridge, UK, and Institute of Biochemistry II, Frankfurt am Main, Germany where he worked on the structure of deubiquitinase. He was Group leader of Structural biology group, BMLS until he joined SGC in 2018.

 

 

Benedict-Tilman Berger
Email: b.berger (at) chemie.uni-frankfurt.de
Tel: +49 (0)69 798-42521

Benedict-Tilman Berger studied Biochemistry at the Freie Universität Berlin. Both his Bachelor thesis (Bayer HealthCare, Department of Screening) and his Master thesis (SGC Oxford, Department of Protein Kinases and Chemical/Structural Biology) focused on binding kinetics of protein kinase inhibitors and possible structural explanations for a slow binding of compounds, which might be a parameter for drug optimization in terms of selectivity, safety or dosing intervals. In 2016, he joined the group of Prof. Stefan Knapp at the SGC site in Frankfurt am Main to work on his PhD thesis. He is following up on his previous work on kinases, using more advanced techniques, e.g., the NanoBRET cellular target engagement assay, to explain in vitro and in vivo binding kinetics of kinase-ligand interactions on a structural level. Currently, he is studying off-rate influenced side effects of inhibitors binding STK10/SLK as an off-target and investigates structure-kinetic relationships for FAK/PYK2, DDR1/DDR2 and LIMK1/LIMK2.

 

 

Jelena Bozilovic
Email: bozilovic (at) chemie.uni-frankfurt.de
Tel: +49 (0)69 798-29317

Jelena obtained her PhD from the Institute of Organic Chemistry and Chemical Biology at Goethe University Frankfurt in 2008, followed by postdoctoral work at the same institute. The main focus of her work was on the development of synthetic oligonucleotides for therapeutic use (antisense oligonucleotides and RNAi). She also played a leading role in setting up a start-up company developing methods for analyzing viral genotypes. In 2016, she joined the group of Prof. Knapp as a medicinal chemist and is currently working on the synthesis and development of molecules for the targeted degradation of kinases and bromodomains in cancer therapy (PROTACs).

 

 

Ralf Braden
Email: Braden (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29317

 

 

 

 

 

 

 

Kathrin Cartsburg
Email: cartsburg (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29917

Kathrin is managing the office of Stefan Knapp’s group. She did her education in Berlin as an industrial management assistant. In the past she was working for different companies in Berlin, Bremen and Frankfurt in the sales department and office organization.

 

 

 

 

Apirat Chaikuad
Email: apirat.chaikuad (at) sgc.ox.ac.uk
Tel: +49 (0)69 798-29401

Apirat Chaikuad is a senior scientist at Frankfurt University. He studied biology at Chulalongkorn University (Thailand) and later did a PhD in structural biology at University of Bristol (UK). He joined the Structural Genomics Consortium at the University of Oxford in 2008 to work with Frank von Delft in the crystallography team. During this time, he successfully developed the newly-minimized BCS crystallization screen by incorporating a novel defined PEG smears method, which is now commercially available. He was also awarded the Emanoel Lee Junior Research Fellowship from St Cross College and a merit award from University of Oxford. Later, he has joined the team of Prof. Stefan Knapp. His current research interests focus primarily on structural biology and chemical biology of signaling pathway, essentially protein kinases.

 

 

Deep Chatterjee
Email: chatterjee (at) nmr.uni-frankfurt.de
Tel: +49 (0)69 798-29872

Deep Chatterjee received his Master's degree in Microbiology from University of Calcutta, Kolkata, India. He then moved to Goethe-Universität Frankfurt, Germany for his doctoral studies, with a focus on NMR characterization of membrane and soluble proteins. In 2017, he joined the group of Prof. Stefan Knapp as a postdoc. He is funded by the Michael J. Fox Foundation to study the protein kinase LRRK2, which is involved in Parkinson's disease.

 

 

 

Anja Dölle
Email: doelle (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29915

Anja Dölle obtained a Bachelor’s degree in chemistry from the university of Würzburg in 2015, followed by a Master’s degree from the University of Frankfurt in 2017. During her master thesis she focused on the synthesis of PROTAC molecules to target bromodomain containing proteins. In April 2018, she started her PhD in the lab of Prof. Stefan Knapp at the Institute of Pharmaceutical Chemistry, working on the development of PROTAC molecules to validate the inhibition of oncoprotein MYC. Her research is funded by the federal ministry of education and research of Germany.

 

 

 

 

Volker Dötsch
Email: vdoetsch (at) em.uni-frankfurt.de
Tel: +49 (0)69 798-29631

 

 

 

 

 

 

Thomas Hanke
Email: hanke (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29313

Thomas Hanke studied Pharmacy at the Goethe University in Frankfurt. In 2014, he completed his PhD in the field of pharmaceutical chemistry, investigating the synthesis and pharmacological characterization of dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors as a new alternative strategy for anti-inflammatory drugs. In 2015, he joined Stefan Knapp´s group where he is working on the development of chemical probes for targeting kinases. For that, he is pursuing different strategies, including the synthesis of allosteric kinase inhibitors (e.g. for LIMK1/2) and the synthesis of macrocyclic compounds to generate new chemistry for targeting kinases.

 

 

David Heidenreich
Email: heidenreich (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29401

"The transcription of genes is dependent on modifications on histones and on the DNA level which is referred to as "epigenetic code". Epigenetic reader domains recruit complexes to modified sites and therefore regulate transcription. Many cancer types exploit aberrant epigenetic landscapes to drive the transcription of oncogenes. My research focusses on protein-protein interactions, which lead to expression of oncogenes. In particular, I am interested in inhibition of reader domains which recognize acetylated histone lysine residues."

 

 

Andreas C. Joerger
Email: joerger (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29872

Andreas C. Joerger obtained his doctoral degree from the University of Freiburg, Germany in 2000 for elucidating the reaction mechanism and structural basis of substrate specificity of a zinc-dependent aldolase. He then assumed a postdoc position in the group of Prof. Sir Alan Fersht at the Medical Research Council (MRC) Centre for Protein Engineering in Cambridge, United Kingdom, initially working on protein design. He stayed on as a senior scientist in structural biology until 2010, before moving to the MRC Laboratory of Molecular Biology in Cambridge (2010-2015). During his long spell at the MRC, he made key contributions towards unraveling the complex structural biology of the tumor suppressor p53 and related proteins. He determined the first crystal structures of p53 cancer mutants, which led to the Y220C mutant being used as a paradigm for the development of mutant p53 rescue drugs based on protein stabilization. In 2016, Dr. Joerger joined the group of Prof. Stefan Knapp at the Institute of Pharmaceutical Chemistry at Goethe University, Frankfurt am Main. He is currently a German Research Foundation (DFG)-funded project leader on targeting the p53 mutome for cancer therapy; and co-investigator on a grant from Worldwide Cancer Research for the development of Y220C mutant stabilizers. His other research interests include the evolutionary history of the p53 pathway, epigenetic targets and general principles of molecular interactions.

 

 

Susanne Müller-Knapp
Email: susanne.mueller-knapp (at) bmls.de
Tel: +49 (0)69 798-42535

Knapp studied Human Biology in Marburg Germany followed by a PhD in molecular biology at the Karolinska Institute in Stockholm, Sweden (1997). She then had more than 6 years of postdoctoral training in the area of inflammation and gene regulation at the Karolinska Institute and at the DIBIT San Raffaele Scientific Institute in Milan, Italy.

In 2004 Susanne joined the Structural Genomics Consortium, SGC, in Oxford. The SGC is an international public private partnership that currently comprises 8 international pharmaceutical companies and a large network of academic and industrial collaborators. Susanne worked at the SGC first as External Research Manager and then Scientific Coordinator. She has been the Project Manager of the Epigenetic Probe Project, which generates tool compounds with defined specificity and selectivity for epigenetic targets and the cell based assay group at the SGC in Oxford testing the cellular activity of the in vitro characterised tool compounds. In her role as Chief Operating Officer at the SGC Frankfurt Susanne is now coordinating several probe programs including the global SGC kinase chemical probe program and the donated probe program, which makes probes available from the pharmaceutical partners of the SGC.

 

 

Andreas Krämer
Email: kraemer (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29872

Andreas Krämer graduated with a diploma in Chemistry from the University of Freiburg in 2012. During his PhD thesis at the University of Darmstadt (2013-2017), he focused on structural studies of bacterial members of the histone deacetylase superfamily (HDAC). After completing his PhD, he joined the group of Stefan Knapp at the SGC Frankfurt as a postdoc. He is currently funded by the Wellcome Trust, working on the structure-based development of selective and potent CaMK1D kinase inhibitors for the treatment of highly aggressive subtypes of breast cancer.

 

 

Christian Kurz
Email: kurz (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29874

Christian Kurz graduated with a Master's degree in Chemistry at the Johann Wolfgang Goethe University, Frankfurt am Main in 2017. In his Master's thesis project, he developed new synthetic routes for inhibitors of metallo-β-lactamases. He then joined the Knapp group at the SGC site Frankfurt to start his doctoral work on the synthesis of macrocyclic kinase inhibitors.

 

 

Romain Lucas
Email: lucas (at) pharmchem.uni-frankfurt.de
Tel: + 49 (0)69 798-29874

Romain Lucas studied Pharmacy in France at the University of Bordeaux Segalen and obtained a Master´s degree in Structural Biochemistry. At the end of 2014, he obtained his doctoral degree from the University of Paris Descartes for the total synthesis of a natural DYRK1A kinase inhibitor performed at “ManRos-Therapeutics”, a biotech company located in Roscoff (France). He stayed for several months at ManRos Therapeutics, working on various projects as a chemist. In 2016, he worked as a post-doctoral researcher at CEA-Saclay. He then worked as a pharmacist, before joining Stefan Knapp´s group in 2018 where he is focusing on the design and synthesis of inhibitors with dual BET bromodomain and HDAC activity.

 

 

Mishal Mariam
Email: mariam (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29872

Mishal obtained a Bachelor in Chemistry from Forman Christian College University Lahore, Pakistan, followed by a Master's degree in Research Chemistry from University of Eastern Finland. She is currently working in the Knapp group for a European consortium called PDZ network. Her research is focused on the structure and function of modular proteins that organize multiple PDZ domains into supramodules, e.g., membrane-associated guanylate kinases (MAGUKs). She is studying the structure and substrate specificity of these multi-domain assemblies, with the goal to elucidate their function in cellular signaling and to exploit the possibility of the development of protein-protein interaction inhibitors targeting PDZ supramodules.

 

 

Xiaomin Ni
Email: ni (at) em.uni-frankfurt.de
Tel: +49 (0)69 798-29872

Xiaomin obtained her Master's degree from China Agricultural University in 2014. Then she worked at the Institute of Aging Research (Hangzhou Normal University), investigating the interaction between tryptophanyl-tRNA synthetase and vascular endothelial cadherin. In April 2017, she joined Stefan's team as a PhD student. She is currently working on structural and mechanistic studies of the interaction of FUSE binding protein 1 (FUBP1) with DNA and the development of FUBP1 inhibitors for cancer therapy.

 

 

Vladimir Rogov
Email: rogov (at) bpc.uni-frankfurt.de
Tel: +49 (0)69 798-29622

Vladimir Rogov obtained his PhD in thermodynamics of protein folding and protein-protein interactions at the Institute of Protein Research, Pushchino, Russia, in the lab of Peter Privalov (1995). He continued his career as a senior scientist at the same institute and as a visiting researcher at University of Frankfurt, Germany (lab of Heinz Rüterjans, 1997-2004). He joined the lab of Volker Dötsch at the Institute of Biophysical Chemistry in 2004. Since 2010 Vladimir leads a research group studying protein-protein and protein-ligand interactions across autophagy and ubiquitination pathways. His main research interests include the characterization of affinity, specificity and driving forces of interactions between human autophagy modifiers (LC3/GABARAP proteins) and a broad spectrum of LIR-containing proteins/peptides by several biophysical and biochemical methods, as well as structural aspects of these interactions. He is also focused on molecular mechanisms of enhancing/reducing of the interactions affinity and specificity by post-translational modifications.

 

 

Sandra Röhm
Email: roehm (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29313

Sandra Röhm studied Biomedical Chemistry at the Johannes Gutenberg University of Mainz, Germany. She did her diploma thesis at the Max Planck Institute for Polymer Research, where she developed novel fluorescent dyes for staining biomolecules inside living cells. She was awarded the Adolf Todt prize for her studies and graduated with a Diploma degree in Chemistry in 2014. Sandra started her PhD in Stefan Knapp's group in 2015. Her main research interest is to investigate new kinase inhibitors which bind to a unique P-loop conformation of p38 MAPK. Furthermore, she is currently working on the development of a potent and selective probe for the inhibition of discoidin domain receptor tyrosine kinase (DDR).

 

 

Nadine Ruß
Email: russ (at) chemie.uni-frankfurt.de
Tel: +49 (0)69 798-29317

Nadine Ruß obtained her Master's degree in Chemistry at the University of Frankfurt, Germany, with the research topic "Role of the kinase P-loop in p38 ligand-binding selectivity". In December 2016, she started her PhD in the lab of Prof. Stefan Knapp at the Institute for Pharmaceutical Chemistry, focusing on the synthesis and optimization of type I/II kinase inhibitors targeting MEK7 and the pseudokinase CASK.

 

 

Martin Schröder
Email: m.schroeder (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29401

Martin Schröder graduated with a degree in Pharmacy from Ludwig-Maximilians-Universität München in 2015. During the last year of his degree, he has spent 6 months at the SGC Oxford working on the biophysical characterization of novel kinase inhibitors. In 2016, he moved to Frankfurt to start as a PhD student at the local SGC site. The focus of his work is on the discovery of features that govern structural flexibility and plasticity in kinases for a better understanding of allosteric kinase regulation.

 

 

Alexandra Stolz
Email: stolz (at) em.uni-frankfurt.de
Tel: +49 (0)69 798-29401

Alexandra Stolz studied Biochemistry in Regensburg, Germany followed by a PhD in yeast genetics and molecular biology in Stuttgart, Germany. After a postdoc (2012-2013) working on ER associated protein degradation (ERAD) – a proteasome dependent pathway, Alexandra joined the groups of Andreas Ernst and Ivan Dikic at IBC2 in Frankfurt, Germany (2013-2016) to work on autophagy. Besides contributing to the characterization of the first autophagy receptor for ER-phagy FAM134B and elaborating the role of the kinase TBK1 in mitophagy, she utilized phage display and protein engineering to develop fluorescent sensors for the central autophagy components LC3/GABARAPs. In January 2017, she joined Genentech in South San Francisco, United States as a visiting scientist where she studied the impact of oncogene-induced secretion during cancer pathogenesis. From February 2018, Alexandra is a team leader of the autophagy probe program, which aims to target different autophagy components including kinases, autophagy receptors and individual LC3/GABARAPs to block or enhance specific canonical and non-canonical autophagy pathways.

 

 

Roberta Tesch
Email: tesch (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29915

Roberta Tesch studied Pharmacy at Estácio de Sá University (Rio de Janeiro, Brazil). She did her Master’s thesis at Federal University of Rio de Janeiro (UFRJ) in the group of Prof. Eliezer J. Barreiro, where she worked on in silico studies of adenosine receptors to understand the subtype selectivity of agonists/antagonists. For her PhD thesis in the same group, she focused on the application of virtual screening protocols to identify potential new scaffolds for protein kinases. During her PhD, she was awarded a one-year scholarship to work in the group of Prof. Daniel Rauh (Dortmund, Germany) on structural biology, particularly on protein kinase crystallization. After a postdoc period in the group of Prof. Stefan Laufer (Tübingen, Germany) applying Structure-Based Drug Design on protein kinases, she joined the group of Prof. Stefan Knapp in May 2018. Currently, she is focusing on the structural biology of salt-inducible kinases (SIKs) by using conventional and in silico methods to guide the design of recombinant proteins and establish a structural model.

 

 

Marek Wanior
Email: wanior (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29317

Marek Wanior received his MSc in Chemistry at the University of Frankfurt and the Buchmann Institute for Molecular Life Sciences in 2015, where he worked on the cloning and expression of a bacterial multifunctional polyketide synthase, supervised by Prof. Martin Grininger. In August 2015, he joined the group of Prof. Stefan Knapp at the Institute for Pharmaceutical Chemistry, working on the synthesis of bromodomain inhibitors and PROTAC molecules targeting the subfamily VIII. His research is funded by the Else-Kröner-Fresenius Foundation and the Translational Research Innovation Pharma program.

 

 

Tim Weiser
Email: weiser (at) pharmchem.uni-frankfurt.de
Tel: +49 (0)69 798-29874

Tim Weiser graduated with a Master's degree in Chemistry at the Johann Wolfgang Goethe University in Frankfurt am Main in 2016. During his Master's thesis project, he synthesized dual sEH/FXR modulators to counter nonalcoholic steatohepatitis. Since 2016, he is developing dual BET/HDAC inhibitors in the group of Stefan Knapp at the SGC site Frankfurt.